Gilead Sciences (GILD) Common Equity (2009 - 2026)

Gilead Sciences (GILD) has reported Common Equity for 18 consecutive years, with $11.8 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Common Equity fell 39.62% year-over-year to $11.8 billion; the trailing twelve-month figure through Jun 2026 stood at $11.8 billion (down 39.62% YoY), and the FY2025 full-year result was $22.7 billion, up 17.96% from the prior year.
• Common Equity slipped to $11.8 billion in Q2 2026 per GILD's latest filing, from $23.4 billion in the prior quarter.
• Across five years, Common Equity topped out at $23.4 billion in Q1 2026 and bottomed at $11.8 billion in Q2 2026.
• Historically, Common Equity has averaged $20.0 billion across 5 years, with a median of $20.6 billion in 2022.
• The widest YoY moves for Common Equity: up 22.82% in 2026, down 39.62% in 2026.
• Over 5 years, Common Equity stood at $21.2 billion in 2022, then grew by 7.26% to $22.7 billion in 2023, then decreased by 15.4% to $19.2 billion in 2024, then gained by 17.96% to $22.7 billion in 2025, then tumbled by 47.9% to $11.8 billion in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $11.8 billion, $23.4 billion, and $22.7 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.